Postoperative Cognitive Dysfunction (POCD)

Modern Terminology: Perioperative Neurocognitive Disorders (PND)

The older term "POCD" broadly referred to what is now categorized as delayed NCD. For exam purposes, POCD = decline in cognition temporally associated with surgery, persisting beyond the acute delirium period.

Definition

• It is not delirium - POCD lacks the acute fluctuating course and impaired level of consciousness that characterise delirium
• Patients are often unaware of it; relatives may first notice the change

Incidence

By 3 months, POCD is almost exclusively a problem in older patients. By 1 year, well-controlled studies show little or no demonstrable cognitive decline attributable to anaesthesia alone. (Barash, 9e)

Pathophysiology

1. Neuroinflammation (Central Mechanism)

• Surgery triggers a systemic inflammatory response; cytokines (IL-1β, IL-6, TNF-α) cross the blood-brain barrier
• This activates microglia and astrocytes, leading to neuroinflammation
• Hippocampus (memory centre) is particularly vulnerable
• Volatile anaesthetics amplify neuroinflammation in animal models via NLRP3 inflammasome activation
• Recent reviews (Liu et al., 2023, PMID: 37748409) identify neuroinflammation as the central enabler of POCD

2. Mitochondrial Dysfunction

• Anaesthetic agents and surgical stress impair mitochondrial electron transport chain
• Leads to increased reactive oxygen species (ROS), oxidative stress, and neuronal apoptosis
• Mitochondria-mediated apoptosis affects hippocampal neurons preferentially (Zhang et al., 2024, PMID: 39533332)

3. Neurotransmitter Imbalance

• Cholinergic hypothesis: Anticholinergic burden disrupts cholinergic neurotransmission critical for memory and attention
• Dopaminergic dysregulation: Contributes to executive dysfunction
• GABA/NMDA imbalance: Volatile agents and benzodiazepines enhance GABAergic signalling while suppressing NMDA-mediated plasticity

4. Decreased BDNF (Brain-Derived Neurotrophic Factor)

• BDNF is critical for neuronal plasticity and memory consolidation
• Anaesthetic gases reduce BDNF concentration in hippocampus in animal models

5. Cerebral Hypoperfusion / Microemboli

• Particularly relevant in cardiac surgery (cardiopulmonary bypass)
• Microemboli, hypoperfusion, and inflammatory mediators from bypass circuit contribute
• Cerebral oximetry-guided management can reduce POCD incidence in cardiac surgery

6. Opioid-Mediated Limbic Activation

• Perioperative opioid use (especially meperidine) activates limbic areas
• APOE ε4 genotype amplifies this risk (Miller's 10e)

7. Sleep Deprivation and Circadian Disruption

• Postoperative sleep disruption impairs memory consolidation and cognitive recovery

Risk Factors

Patient (Predisposing) Factors

• Advanced age (most consistent risk factor)
• Pre-existing cognitive impairment or dementia
• Lower education level and lower baseline IQ
• Prior stroke (even without residual deficit)
• Frailty
• Depression and anxiety
• APOE ε4 genotype
• Parkinson's disease
• Renal impairment
• Diabetes mellitus

Surgical (Precipitating) Factors

• Major surgery (cardiac > orthopaedic > abdominal)
• Longer duration of surgery
• Emergency procedures
• Greater intraoperative blood loss
• Hypotension / hypoperfusion
• Hypothermia

Anaesthetic (Precipitating) Factors

• Benzodiazepines (premedication)
• Anticholinergics (especially centrally acting: scopolamine, atropine)
• Meperidine (pethidine) - highest opioid risk
• Excessive anaesthetic depth (burst suppression on EEG)
• General anaesthesia > regional anaesthesia (early postop only; no difference at 3 months)

Postoperative Factors

• Uncontrolled pain
• Opioid analgesics
• Sleep deprivation
• Electrolyte disturbances
• Polypharmacy ("Beers list" drugs)
• ICU admission / unfamiliar environment
• Urinary catheterisation, constipation

Clinical Features

• Impaired memory (recent > remote)
• Reduced concentration and attention
• Slowed information processing speed
• Impaired executive function
• Reduced verbal fluency (e.g., fewer animals named in 1 minute)
• Changes noticed by family before the patient
• No fluctuation and no altered consciousness (distinguishes from delirium)
• Often resolves within weeks to months; can rarely persist

Diagnosis

Neuropsychological Test Battery (measures multiple domains):

• Mini-Mental State Examination (MMSE) - screening only, not sensitive enough
• Montreal Cognitive Assessment (MoCA) - preferred screening tool
• Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)
• Trail Making Test (executive function)
• Digit Span (working memory)
• Rey Auditory Verbal Learning Test (verbal memory)
• Grooved Pegboard (psychomotor speed)

Diagnostic Criterion:

• Decline of ≥1-2 standard deviations below preoperative baseline in ≥2 cognitive domains (Z-score method)
• OR significant change on reliable change index accounting for practice effects

Screening Tools for Delirium (POD - NOT POCD):

• CAM (Confusion Assessment Method) - gold standard
• CAM-ICU (for intubated patients)
• 4AT (rapid bedside tool)
• MMSE + observation

Key Differentials:

Prevention

Preoperative:

1. Identify high-risk patients: Screen all patients ≥65 years with MoCA or similar; document baseline
2. Optimise medical comorbidities (diabetes, hypertension, heart failure)
3. Counsel patient and family about POCD risk
4. Consider prehabilitation and cognitive training
5. Avoid preoperative benzodiazepines (especially in elderly)
6. Geriatrician/neurologist involvement for high-risk cases
7. Medication reconciliation - identify and stop Beers list drugs

Intraoperative:

1. EEG-guided depth of anaesthesia monitoring (BIS/Entropy) - limit burst suppression, target adequate alpha power; reduces POD in first 5 days and may lessen cognitive impairment at 1 year
2. Avoid excessive anaesthetic depth (deep anaesthesia / burst suppression correlates with delirium)
3. Cerebral oximetry (NIRS) - correct cerebral oxygen desaturation, particularly in cardiac surgery
4. Avoid hypotension relative to patient's individual BP range
5. Maintain normothermia
6. Avoid centrally acting anticholinergics, benzodiazepines, and meperidine
7. Multimodal analgesia - minimise opioid requirement
8. Regional anaesthesia (where feasible) - slightly better early cognitive outcomes; no difference at 3 months
9. Monitor age-adjusted end-tidal MAC fraction
10. N2O: does not appear to worsen short-term cognitive outcomes when added to volatile agents

Postoperative:

1. Multimodal non-opioid pain control (NSAIDs, paracetamol, regional techniques, ketamine, dexmedetomidine)
2. Hospital Elder Life Program (HELP) - reduces delirium incidence by up to 40%:
   • Early mobilisation
   • Sleep hygiene protocols (noise reduction, light/dark cycles)
   • Orientation aids (clocks, calendars, familiar objects)
   • Hydration and nutrition
   • Visual and hearing aids (glasses, hearing aids)
   • Cognitive activities
3. ABCDEF Bundle (ICU): Awakening, Breathing, Coordination, Delirium screening, Early mobility, Family engagement
4. Correct electrolyte disturbances, avoid urinary retention
5. Minimise polypharmacy
6. Regular delirium screening (CAM) - once preoperatively, then daily
7. Family involvement and familiar environment

Anaesthetic Choice and POCD

General vs. Regional Anaesthesia:

• Early postop (<1 week): General anaesthesia produces slightly more cognitive decline than regional (propofol < desflurane < sevoflurane in degree of early decline)
• At 3 months: No significant difference between GA and regional anaesthesia (Barash, 9e)
• At 1 year: No demonstrable difference

TIVA vs. Inhalational:

• Some evidence favours TIVA (propofol-based) for reduced early cognitive impairment
• Conflicting literature - differences may reflect dosing regimens rather than intrinsic agent properties (Miller's 10e)

Xenon:

• Faster emergence than other agents; may reduce early POCD
• Benefit does not extend beyond 2-3 days postop
• Does not reduce incidence of POCD in cardiac or non-cardiac surgery on systematic review
• Neuroprotective potential remains debatable

Dexmedetomidine:

• Some studies show protective effects on POD; no definitive benefit on POCD established
• Useful as part of opioid-sparing multimodal analgesia

Treatment

1. Identify and correct reversible causes (hypoxia, electrolytes, pain, infection, medications)
2. Involve relatives/carers - familiar faces reduce disorientation
3. Non-pharmacological delirium management (HELP programme)
4. Cognitive rehabilitation post-discharge
5. Haloperidol - used as last resort for agitated hyperactive delirium only; does NOT prevent or treat POCD; does not reduce duration or severity of delirium
6. Antipsychotics are not recommended for POCD prevention

Prognosis

• Most patients recover within weeks to months
• POCD at hospital discharge predicts POCD at 3 months
• Increased 1-year mortality in patients with cognitive decline at both discharge and 3 months
• In patients with pre-existing Alzheimer pathology, surgery does not accelerate the overall rate of decline
• Long-term severe POCD (>1 year) is uncommon in otherwise healthy individuals
• Cardiac surgery patients have higher and more prolonged incidence

Exam High-Yield Points

• POCD ≠ Delirium (no fluctuation, no altered consciousness, no acute onset)
• Biggest risk factor = advanced age
• Most important intraoperative intervention = EEG-guided anaesthesia depth + cerebral oximetry
• No difference in POCD at 3 months between GA and regional anaesthesia
• No proven pharmacological treatment for POCD; prevention is key
• Avoid: benzodiazepines, meperidine, centrally acting anticholinergics, deep anaesthesia, hypotension
• HELP programme reduces delirium by up to 40%
• Modern term = Perioperative Neurocognitive Disorder (PND); DSM-5 aligned
• The central pathophysiological mechanism is neuroinflammation